Jun Fang

Biomaterials · Advanced Drug Delivery Reviews · 2006–2020

A researcher in the Science corpus: 4 papers; trusts 2 researchers and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

Whom Jun Fang trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. H. Maeda
  2. R. Duncan

Who trusts Jun Fang overall

  1. Jun Wu
  2. H. Maeda
  3. M. Ernsting
  4. F. Danhier
  5. Hisataka Kobayashi
  6. A. Anselmo

Papers from Jun Fang's perspective

Ordered by how strongly the researchers Jun Fang trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Delivering nanomedicine to solid tumors (Nature Reviews Clinical Oncology)
  2. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (Journal of Clinical Oncology)
  3. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (Science Translational Medicine)
  4. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. (Progress in lipid research)
  5. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (Proceedings of the National Academy of Sciences of the United States of America)
  6. Openings between defective endothelial cells explain tumor vessel leakiness. (American Journal of Pathology)
  7. Pathology: Cancer cells compress intratumour vessels (Nature)
  8. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors (Cancer Research)
  9. Ligand-targeted therapeutics in anticancer therapy (Nature Reviews. Cancer)
  10. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. (Cancer Research)

Their papers